Roivant Sciences Ltd.
ROIV
$28.58
-$0.95-3.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -66.71% | -77.83% | -64.89% | -72.84% | -16.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.71% | -77.83% | -64.89% | -72.84% | -16.08% |
| Cost of Revenue | 37.38% | 18.50% | 16.10% | 28.30% | 36.90% |
| Gross Profit | -43.12% | -25.12% | -18.75% | -35.58% | -41.83% |
| SG&A Expenses | -23.99% | 32.27% | -34.01% | 37.88% | 128.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.11% | 25.19% | -13.03% | 32.50% | 81.24% |
| Operating Income | -1.27% | -28.71% | 12.33% | -36.63% | -85.71% |
| Income Before Tax | 323.63% | -23.82% | 29.12% | -1,270.99% | -101.58% |
| Income Tax Expenses | 99.41% | 191.25% | -43.85% | -61.14% | 954.34% |
| Earnings from Continuing Operations | 240.96% | -50.14% | 29.89% | -766.72% | -165.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -214.92% | -6.81% | 5.59% | 33.72% | 46.27% |
| Net Income | 246.75% | -256.98% | 50.68% | -334.38% | -36.63% |
| EBIT | -1.27% | -28.71% | 12.33% | -36.63% | -85.71% |
| EBITDA | -3.41% | -29.41% | 12.10% | -37.47% | -95.25% |
| EPS Basic | 247.82% | -262.80% | 46.74% | -353.51% | -55.10% |
| Normalized Basic EPS | -78.70% | -103.08% | -10.83% | -131.73% | -257.53% |
| EPS Diluted | 195.37% | -264.13% | 45.69% | -354.83% | -56.00% |
| Normalized Diluted EPS | -54.44% | -103.08% | -10.83% | -146.22% | -257.53% |
| Average Basic Shares Outstanding | -0.73% | -3.58% | -7.41% | -7.55% | -11.90% |
| Average Diluted Shares Outstanding | 14.84% | -3.58% | -7.41% | -12.97% | -11.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |